Ultralow Dose PET Imaging for Parkinson's Disease and Brain Tumors

This trial tests a new imaging technique for detecting and monitoring Parkinson’s disease and certain brain tumors. It uses a much lower radiation dose than usual methods. Participants will receive a small amount of a radioactive substance, 18F-FDOPA (a tracer used in PET scans), and undergo a PET scan to determine if researchers can improve the imaging process. Suitable candidates include those diagnosed with Parkinson’s disease or specific brain tumors, who do not have severe claustrophobia or conditions that make long scans uncomfortable. As a Phase 2 trial, this research measures how well the imaging technique works in an initial, smaller group, offering participants a chance to contribute to advancements in medical imaging.

The trial protocol does not specify if you need to stop taking your current medications, but it mentions that treatments interfering with the study may be excluded. It's best to discuss your medications with the study team.

Previous studies have shown that 18F-FDOPA PET imaging is generally safe. Most people tolerate it well, and serious side effects rarely occur. The scan uses low radiation, but there is a small risk from exposure, so the lowest possible dose is used. The FDA has approved this technique for certain conditions, such as Parkinson's disease, indicating its safety for those uses. Overall, research suggests that 18F-FDOPA is a well-tolerated option for imaging various brain conditions.¹²³⁴⁵

Researchers are excited about ultralow dose 18F-FDOPA PET imaging because it offers a new approach to diagnosing Parkinson's disease and brain tumors with significantly reduced radiation exposure. Unlike standard PET imaging, which uses higher doses of radiotracers, this method reduces radiation doses by 10-100 times while still aiming to maintain high-quality images. This advancement could make the diagnostic process safer for patients, especially those who require repeated imaging, and could lead to more precise timing and reconstruction of images.

This trial will evaluate ultralow dose 18F-FDOPA PET imaging for Parkinson's disease and brain tumors. Studies have shown that 18F-FDOPA PET imaging effectively diagnoses and manages these conditions. Research indicates that 18F-FDOPA surpasses other imaging methods in accuracy, particularly for identifying low-grade tumors and assessing recurring tumors. The FDA has approved 18F-FDOPA for early Parkinson's disease diagnosis, highlighting its proven effectiveness. This imaging technique visualizes the brain's dopamine pathways, crucial for understanding conditions like Parkinson's. Overall, 18F-FDOPA PET imaging is a well-supported tool for evaluating both Parkinson's and brain tumors.¹²⁶⁷⁸